Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T

[1]  M. Wills,et al.  Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers , 2021, Immunology.

[2]  K. Brengel-Pesce,et al.  Specific detection of memory T‐cells in COVID‐19 patients using standardized whole‐blood Interferon gammarelease assay , 2021, European journal of immunology.

[3]  S. Barış,et al.  Adverse COVID‐19 outcomes in immune deficiencies: Inequality exists between subclasses , 2021, Allergy.

[4]  J. V. Van Eyk,et al.  Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 , 2021, Nature Medicine.

[5]  J. Stanek,et al.  COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients , 2021, Journal of Infection.

[6]  Janet S. Lee,et al.  Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[7]  Michele D. Sobolewski,et al.  Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  William L. Hamilton,et al.  Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report , 2020, Nature Communications.

[9]  S. Bhat,et al.  SARS-CoV-2: A critical review of its history, pathogenesis, transmission, diagnosis and treatment , 2020, Biosafety and Health.

[10]  Elisabeth Mahase.  Covid-19: RECOVERY trial will evaluate “antiviral antibody cocktail” , 2020, BMJ.

[11]  H. Harapan,et al.  Remdesivir and its antiviral activity against COVID-19: A systematic review , 2020, Clinical Epidemiology and Global Health.

[12]  U. Reimer,et al.  SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.

[13]  O. Kirk,et al.  Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy , 2020, The Journal of infectious diseases.

[14]  J. Miskoff,et al.  Novel coronavirus 2019 (COVID-19) , 2020, Medicine.

[15]  T. Jodlowski,et al.  Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.